This is a routine board appointment with no financial data or strategic changes. Monitor next quarterly earnings for any operational updates or guidance changes.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 23 $529.53entry
- T+1 · 4mo ago −0.20%α −0.30% · $528.47
- T+5 · 4mo ago −0.70%α −1.18% · $525.82
- T+20 · 3mo ago −2.08%α −5.39% · $518.50
- T+60 · 5w ago +2.26%α −2.29% · $541.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics appointed Victor Dzau, M.D., former President of the National Academy of Medicine, to its Board of Directors on July 22, 2026. This is a routine board refreshment appointment of a highly credentialed academic and healthcare leader, with no material financial impact or change in corporate strategy disclosed. The filing contains no financial data, guidance, or operational updates.
Key Facts
- Board size increased to 13 members with the appointment of Victor Dzau, M.D.
- Dr. Dzau recently completed a 12-year tenure as President of the National Academy of Medicine.
- Dr. Dzau received initial equity grants of 380 RSUs and 1,190 stock options, plus pro-rata grants of 350 RSUs and 1,110 stock options for the remainder of the 2026-2027 board service year.
- No material transactions between Dr. Dzau and the company exceeding $120,000.
- The appointment is part of a 'concerted Board refreshment effort' as stated by the company.
Financial Impact
No material financial impact. Director equity grants are standard and immaterial relative to a $22.7B market cap.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-086068 |
| Document: tm2620809d1_ex99-1.htm | 0001104659-26-086068 |
| Document: 0001104659-26-086068-index-headers.html | 0001104659-26-086068 |
| Document: 0001104659-26-086068-index.html | 0001104659-26-086068 |
| Document: 0001104659-26-086068.txt | 0001104659-26-086068 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers